Functional and Quality of Life Effects of the Mollii Neuromodulatory Suit in Patients With Stroke and Multiple Sclerosis

NCT ID: NCT07333222

Last Updated: 2026-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-12

Study Completion Date

2028-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Objective assessment of clinical symptoms resulting from stroke, as well as changes in mobility and quality of life, and determination of changes resulting from therapies
* Objective assessment of the quality of life, functionality, and clinical symptoms of patients with multiple sclerosis (MS) and determination of changes resulting from therapies
* Comparison of measured data from the two main neurological patient groups (stroke, multiple sclerosis) and follow-up of changes in relation to themselves and each other.
* Mapping the role of the placebo effect in neuromodulation devices by comparing subjective and objective outcomes.
* Analyzing the expectations and experiences of patients receiving placebo treatment using quality of life questionnaires.
* Analyzing the effects of the Mollii suit among subgroups of MS and stroke patients.
* Assessing the safety, possible side effects, and tolerability of the Mollii suit.
* Mapping changes in gait pattern due to the effects of therapy using 3D motion analysis.
* Examining the maintenance effects of neuromodulation during a 1-month follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mollii Group

Receaving treatment with the stimulation program.

Group Type EXPERIMENTAL

the Mollii garment with active stimulation

Intervention Type OTHER

Patients in the Intervention group attend therapy three days a week for four weeks, with each treatment lasting 60 minutes. In this group patients are fitted with the Mollii garment according to the same protocol, but in their case, active stimulation of the prescribed neuromodulation program is initiated.

Control Group

Receaving treatment without the stimulation program.

Group Type PLACEBO_COMPARATOR

Mollii neuromodulation garment, but the stimulation program is not activated (placebo)

Intervention Type OTHER

CG patients are fully equipped with the Mollii neuromodulation garment, but the stimulation program is not activated. The patient thus completes the therapy without the device's perceptible electrical stimulation, preserving the blinding effect of the placebo-controlled setup. The total treatment time, setup process, and therapeutic environment are the same as for the intervention group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

the Mollii garment with active stimulation

Patients in the Intervention group attend therapy three days a week for four weeks, with each treatment lasting 60 minutes. In this group patients are fitted with the Mollii garment according to the same protocol, but in their case, active stimulation of the prescribed neuromodulation program is initiated.

Intervention Type OTHER

Mollii neuromodulation garment, but the stimulation program is not activated (placebo)

CG patients are fully equipped with the Mollii neuromodulation garment, but the stimulation program is not activated. The patient thus completes the therapy without the device's perceptible electrical stimulation, preserving the blinding effect of the placebo-controlled setup. The total treatment time, setup process, and therapeutic environment are the same as for the intervention group.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* suffered a first ischemic stroke, diagnosed by a neurologist based on CT or MR imaging
* neurological examination revealed mobility and postural limitations
* confirmed multiple sclerosis diagnosed by a neurologist based on MRI imaging

Exclusion Criteria

* multiple strokes in medical history
* systolic blood pressure less than 120 or higher than 160 mmHg
* orthostatic hypotension
* arotid artery stenosis
* severe heart disease
* hemophilia
* traumatic brain injury
* seizure disorder
* untreated diabetes
* abnormal electroencephalography
* abnormal blood panel
* use of sedatives
* irregular medication use
* severe aphasia (Western Aphasia Battery ≤ 25)
* severe visual or hearing impairment
* severe sensory dysfunction
* severe orthopedic problems
* other neurological conditions affecting motor function
* alcoholism
* drug use
* smoking after diagnosis of stroke
* unable to walk at least 10 m with or without assistance in 6 minutes
* BBS score ≤ 32
* BI score ≤ 70
* current participation in individual or group exercise program outside of standard physical therapy
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Somogy Megyei Kaposi Mór Teaching Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tollár József

Head of Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

József Dr. habil Tollár

Role: PRINCIPAL_INVESTIGATOR

Somogy County Kaposi Mór Teaching Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Somogy County Kaposi Mór Teaching Hospital

Kaposvár, Somogy County, Hungary

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hungary

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Barbara Kopácsi

Role: CONTACT

+36308340545

József Dr. habil. Tollár

Role: CONTACT

+36306994497

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Barbara Kopácsi

Role: primary

+36308340545

József Dr. habil Tollár

Role: backup

+36306994497

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IG/4390-0/2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.